MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder

Imagem de Miniatura
Arquivos
art_PASSOS_MOGIgGAssociated_Optic_Neuritis_Encephalitis_and_Myelitis_Lessons_Learned_2018.PDF (1.01 MB)
Citações na Scopus
152
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
PASSOS, Giordani Rodrigues dos
COSTA, Bruna Klein da
FUJIHARA, Kazuo
Citação
FRONTIERS IN NEUROLOGY, v.9, article ID 217, 10p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been found in some cases diagnosed as seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG allowed the identification of a subgroup with a clinical course distinct from that of NMOSD patients who are seropositive for aquaporin-4-IgG antibodies. MOG-IgG is associated with a wider clinical phenotype, not limited to NMOSD, with the majority of cases presenting with optic neuritis (ON), encephalitis with brain demyelinating lesions, and/or myelitis. Therefore, we propose the term MOG-IgG-associated Optic Neuritis, Encephalitis, and Myelitis (MONEM). Depending on the clinical characteristics, these patients may currently be diagnosed with NMOSD, acute disseminated encephalomyelitis, pediatric multiple sclerosis, transverse myelitis, or ON. With specific cell-based assays, MOG-IgG is emerging as a potential biomarker of inflammatory disorders of the central nervous system. We review the growing body of evidence on MONEM, focusing on its clinical aspects.
Palavras-chave
neuromyelitis optica spectrum disorder, optic neuritis, myelitis, encephalitis, myelin oligodendrocyte glycoprotein antibody
URI
https://observatorio.fm.usp.br/handle/OPI/26482
Referências
  1. Adelmann M, 1995, J NEUROIMMUNOL, V63, P17, DOI 10.1016/0165-5728(95)00124-7
  2. Akaishi T, 2016, J NEUROL NEUROSUR PS, V87, P446, DOI 10.1136/jnnp-2014-310206
  3. Amano H, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0224-x
  4. Barnett MH, 2012, MULT SCLER J, V18, P108, DOI 10.1177/1352458511421185
  5. Baumann M, 2016, MULT SCLER J, V22, P1821, DOI 10.1177/1352458516631038
  6. Bernard-Valnet R, 2015, EUR J NEUROL, V22, P1511, DOI 10.1111/ene.12679
  7. Bettelli E, 2003, J EXP MED, V197, P1073, DOI 10.1084/jem.20021603
  8. Bettelli E, 2006, J CLIN INVEST, V116, P2393, DOI 10.1172/JCI28334
  9. Bonnan M, 2012, MULT SCLER INT, DOI 10.1155/2012/787630
  10. Brehm U, 1999, J NEUROIMMUNOL, V97, P9, DOI 10.1016/S0165-5728(99)00010-7
  11. Brilot F, 2009, ANN NEUROL, V66, P833, DOI 10.1002/ana.21916
  12. Chalmoukou K, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000131
  13. Cobo-Calvo A, 2016, MULT SCLER J, V22, P312, DOI 10.1177/1352458515591071
  14. Dale RC, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000012
  15. Di Pauli F, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000175
  16. Di Pauli F, 2011, CLIN IMMUNOL, V138, P247, DOI 10.1016/j.clim.2010.11.013
  17. Fernandez-Carbonell C, 2016, MULT SCLER J, V22, P174, DOI 10.1177/1352458515587751
  18. Fujihara K, 2012, CLIN EXP NEUROIMMUNO, V3, P58, DOI 10.1111/J.1759-1961.2012.00030.X
  19. Fujimori J, 2017, J NEUROL NEUROSUR PS, V88, P534, DOI 10.1136/jnnp-2016-315094
  20. Fukushima Naoya, 2017, Rinsho Shinkeigaku, V57, P723, DOI 10.5692/clinicalneurol.cn-001078
  21. Hacohen Y, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000081
  22. Hamid SHM, 2018, JAMA NEUROL, V75, P65, DOI 10.1001/jamaneurol.2017.3196
  23. Hoftberger R, 2015, MULT SCLER J, V21, P866, DOI 10.1177/1352458514555785
  24. Hyun JW, 2015, MULT SCLER J, V21, P710, DOI 10.1177/1352458514551454
  25. Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111
  26. Ikeda K, 2015, MULT SCLER J, V21, P656, DOI 10.1177/1352458514551455
  27. Izaki Shoko, 2013, Rinsho Shinkeigaku, V53, P513
  28. Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0718-0
  29. Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0719-z
  30. Jarius S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0717-1
  31. Jarius S, 2016, MULT SCLER J, V22, P1541, DOI 10.1177/1352458515622986
  32. Johns TG, 1999, J NEUROCHEM, V72, P1, DOI 10.1046/j.1471-4159.1999.0720001.x
  33. Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9
  34. Jurynczyk M, 2017, BRAIN, V140, P617, DOI 10.1093/brain/aww350
  35. Kaneko K, 2016, J NEUROL NEUROSUR PS, V87, P1257, DOI 10.1136/jnnp-2015-312676
  36. Ketelslegers IA, 2015, MULT SCLER J, V21, P1513, DOI 10.1177/1352458514566666
  37. Kim SH, 2012, MULT SCLER J, V18, P1480, DOI 10.1177/1352458512439439
  38. Kim SM, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000163
  39. Kitley J, 2014, J NEUROL SCI, V339, P223, DOI 10.1016/j.jns.2014.01.035
  40. Kitley J, 2014, JAMA NEUROL, V71, P276, DOI 10.1001/jamaneurol.2013.5857
  41. Kitley J, 2012, NEUROLOGY, V79, P1273, DOI 10.1212/WNL.0b013e31826aac4e
  42. Kortvelyessy Peter, 2017, Neurol Neuroimmunol Neuroinflamm, V4, pe335, DOI 10.1212/NXI.0000000000000335
  43. Krishnamoorthy G, 2006, J CLIN INVEST, V116, P2385, DOI 10.1172/JCI28330
  44. Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X
  45. Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304
  46. Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
  47. Mader S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-184
  48. Marignier R, 2013, NEUROLOGY, V80, P2194, DOI 10.1212/WNL.0b013e318296e917
  49. Mayer MC, 2013, J IMMUNOL, V191, P3594, DOI 10.4049/jimmunol.1301296
  50. Mayer MC, 2012, THER ADV NEUROL DISO, V5, P147, DOI 10.1177/1756285611433772
  51. McLaughlin KA, 2009, J IMMUNOL, V183, P4067, DOI 10.4049/jimmunol.0801888
  52. Melamed E, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000134
  53. Min JH, 2012, MULT SCLER J, V18, P113, DOI 10.1177/1352458511431973
  54. Nakajima H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007766
  55. Nakamura Y, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0858-6
  56. Nozaki I, 2006, J NEUROL NEUROSUR PS, V77, P1094, DOI 10.1136/jnnp.2005.086306
  57. O'Connor KC, 2007, NAT MED, V13, P211, DOI 10.1038/nm1488
  58. Ogawa R, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000322
  59. Oshiro Azusa, 2016, No To Hattatsu, V48, P199
  60. Pache F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0720-6
  61. Pandit L, 2015, MULT SCLER J, V21, P845, DOI 10.1177/1352458515572406
  62. Papadopoulos MC, 2014, NAT REV NEUROL, V10, P493, DOI 10.1038/nrneurol.2014.141
  63. Peschl P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00529
  64. Probstel AK, 2011, NEUROLOGY, V77, P580, DOI 10.1212/WNL.0b013e318228c0b1
  65. Probstel AK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0256-1
  66. Ramanathan S, 2018, J NEUROL NEUROSUR PS, V89, P127, DOI 10.1136/jnnp-2017-316880
  67. Ramanathan S, 2016, MULT SCLER J, V22, P470, DOI 10.1177/1352458515593406
  68. Ramanathan S, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000040
  69. Rostasy K, 2013, MULT SCLER J, V19, P1052, DOI 10.1177/1352458512470310
  70. Rostasy K, 2012, ARCH NEUROL-CHICAGO, V69, P752, DOI 10.1001/archneurol.2011.2956
  71. Sakuma H, 2004, BRAIN, V127, P2201, DOI 10.1093/brain/awh260
  72. Sato DK, 2014, ARQ NEURO-PSIQUIAT, V72, P445, DOI 10.1590/0004-282X20140032
  73. Sato DK, 2014, NEUROLOGY, V82, P474, DOI 10.1212/WNL.0000000000000101
  74. Sepulveda M, 2016, J NEUROL, V263, P1349, DOI 10.1007/s00415-016-8147-7
  75. Sepulveda M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000225
  76. Shimizu J, 2010, NEUROLOGY, V75, P1423, DOI 10.1212/WNL.0b013e3181f8832e
  77. Siritho S, 2016, MULT SCLER J, V22, P964, DOI 10.1177/1352458515614093
  78. Spadaro M, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000257
  79. Spadaro Melania, 2016, Methods Mol Biol, V1304, P99, DOI 10.1007/7651_2015_223
  80. Spadaro M, 2015, ANN CLIN TRANSL NEUR, V2, P295, DOI 10.1002/acn3.164
  81. Stiebel-Kalish H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170847
  82. Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x
  83. van Pelt ED, 2016, EUR J NEUROL, V23, P580, DOI 10.1111/ene.12898
  84. von Budingen HC, 2004, EUR J IMMUNOL, V34, P2072, DOI 10.1002/eji.200324843
  85. Wang JJ, 2016, NEUROLOGY, V87, P229, DOI 10.1212/WNL.0000000000002844
  86. Weissert R, 2002, J IMMUNOL, V169, P548, DOI 10.4049/jimmunol.169.1.548
  87. Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729
  88. Woodhall M, 2013, J NEUROL SCI, V335, P221, DOI 10.1016/j.jns.2013.08.034
  89. Yan YP, 2016, SCI CHINA LIFE SCI, V59, P1270, DOI 10.1007/s11427-015-4997-y
  90. Zamvil SS, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000062
  91. Zekeridou A, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000110
  92. Zhou L, 2017, J NEUROIMMUNOL, V305, P19, DOI 10.1016/j.jneuroim.2017.01.007

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/45